Credit: Madrigal Pharmaceuticals. Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network. Rezdiffra should be avoided in ...
Credit: Madrigal Pharmaceuticals. The approval was based on data from the pivotal phase 3 MAESTRO-NASH study, which included patients with biopsy-proven NASH and fibrosis who were on stable doses of ...
Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works. Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help ...
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
CONSHOHOCKEN, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH ...
Millions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced ...
CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...
A chronic metabolic disease in which fat buildup leads to worsening liver function that can ultimately require an organ transplant now has its first FDA-approved therapy, a once-daily pill developed ...
The FDA granted accelerated approval to resmetirom (Rezdiffra) as the first treatment for adults with noncirrhotic non-alcoholic steatohepatitis (NASH), also now referred to as metabolic ...
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported strong third-quarter 2025 results, fueled by accelerating sales of its liver disease drug Rezdiffra™ (resmetirom) and a major ...
Madrigal Pharmaceuticals (MDGL) appears to have a blockbuster on its hands in Rezdiffra™ (resmetirom), the metabolic dysfunction-associated steatohepatitis (MASH) treatment that won an historic FDA ...
Hosted on MSN
Madrigal projects Rezdiffra annualized sales over $1B while expanding payer access and pipeline in 2026
CEO William Sibold reported "We have delivered another excellent quarter as we continue to execute on our strategic priorities," highlighting that Rezdiffra is "quickly becoming one of the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results